| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,830,000 |
| Market
Cap: |
12.75(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.298 - $3.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a hematologic cancer, and potentially other hematologic cancers. Co. is also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. Co. has designed an antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
65,403 |
2,581,565 |
| Total Buy Value |
$0 |
$0 |
$90,256 |
$4,837,462 |
| Total People Bought |
0 |
0 |
1 |
9 |
| Total Buy Transactions |
0 |
0 |
2 |
21 |
| Total Shares Sold |
0 |
0 |
3,700 |
4,053,849 |
| Total Sell Value |
$0 |
$0 |
$7,215 |
$12,677,616 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
6 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barrett M James |
Director |
– • • |
2018-05-10 |
4 |
S |
$17.81 |
$169,890 |
I/I |
(9,539) |
4,995,664 |
|
- |
|
| Barrett M James |
Director |
– • • |
2018-05-10 |
4 |
OE |
$0.33 |
$169,769 |
I/I |
514,452 |
5,001,197 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2018-05-10 |
4 |
S |
$17.81 |
$169,890 |
I/I |
(9,539) |
4,995,664 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2018-05-10 |
4 |
OE |
$0.33 |
$169,769 |
I/I |
514,452 |
5,001,197 |
|
- |
|
| Nea Partners 10 L P |
10% Owner |
– – • |
2018-05-10 |
4 |
S |
$17.81 |
$169,890 |
D/D |
(9,539) |
4,995,664 |
|
- |
|
| Nea Partners 10 L P |
10% Owner |
– – • |
2018-05-10 |
4 |
OE |
$0.33 |
$169,769 |
D/D |
514,452 |
5,001,197 |
|
- |
|
| Thackray Helen M. |
SVP Clinical Development, CMO |
• – – |
2017-12-08 |
4 |
AS |
$15.01 |
$30,020 |
D/D |
(2,000) |
148,615 |
|
- |
|
| Thackray Helen M. |
SVP Clinical Development, CMO |
• – – |
2017-09-18 |
4 |
AS |
$13.00 |
$26,000 |
D/D |
(2,000) |
150,615 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2017-06-15 |
4 |
A |
$11.27 |
$33,810 |
D/D |
3,000 |
8,000 |
|
- |
|
| Thackray Helen M. |
SVP Clinical Development, CMO |
• – – |
2017-05-25 |
4 |
AS |
$15.57 |
$31,140 |
D/D |
(2,000) |
152,615 |
|
- |
|
| Thackray Helen M. |
SVP Clinical Development, CMO |
• – – |
2017-05-19 |
4 |
AS |
$12.14 |
$24,280 |
D/D |
(2,000) |
154,615 |
|
- |
|
| Magnani John L. |
SVP of Research, CSO |
• • – |
2017-05-10 |
4 |
OE |
$1.12 |
$9,999 |
D/D |
8,928 |
99,302 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2017-05-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,020,664 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2016-12-20 |
4 |
B |
$6.01 |
$30,050 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Thackray Helen M. |
VP Clinical Development, CMO |
• – – |
2016-10-03 |
4 |
AS |
$7.00 |
$28,001 |
D/D |
(4,000) |
156,615 |
|
- |
|
| Thackray Helen M. |
VP Clinical Development, CMO |
• – – |
2016-07-20 |
4 |
AS |
$8.00 |
$16,000 |
D/D |
(2,000) |
160,615 |
|
- |
|
| Thackray Helen M. |
VP Clinical Development, CMO |
• – – |
2016-07-06 |
4 |
AS |
$6.68 |
$45,397 |
D/D |
(6,796) |
162,615 |
|
- |
|
| Thackray Helen M. |
VP Clinical Development, CMO |
• – – |
2016-07-05 |
4 |
AS |
$7.01 |
$71,053 |
D/D |
(10,136) |
169,411 |
|
- |
|
| Thackray Helen M. |
VP Clinical Development, CMO |
• – – |
2016-07-01 |
4 |
AS |
$7.40 |
$37,503 |
D/D |
(5,068) |
179,547 |
|
- |
|
| Baldwin John J. |
Director |
– • – |
2016-06-29 |
4 |
OE |
$1.12 |
$678 |
D/D |
605 |
1,210 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2016-03-04 |
4 |
B |
$4.77 |
$49,630 |
D/D |
10,397 |
11,497 |
2.39 |
- |
|
| Top Franklin H Jr |
Director |
– • – |
2016-02-05 |
4 |
OE |
$1.12 |
$13,092 |
D/D |
11,689 |
12,294 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2015-11-16 |
4 |
S |
$6.91 |
$3,123 |
I/I |
(452) |
4,490,751 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2015-11-16 |
4 |
OE |
$0.33 |
$3,117 |
I/I |
9,445 |
4,491,203 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2015-11-16 |
4 |
S |
$6.91 |
$3,123 |
I/I |
(452) |
4,490,751 |
|
- |
|
116 Records found
|
|
Page 4 of 5 |
|
|
0.03 (10.54%) 
